Research indicates blocking SET increases glioblastoma cells' sensitivity to radiation — Evidence Review
Published in Cancer Letters, by researchers from The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Researched by
— the AI search engine for science
Table of Contents
Researchers at The Ohio State University have identified the protein SET as a potential vulnerability in glioblastoma, suggesting that targeting SET could make these aggressive brain tumors more susceptible to radiation and chemotherapy. Related studies broadly support the importance of overcoming treatment resistance in glioblastoma, though direct evidence for SET inhibition's clinical benefit in patients is still lacking; the findings align with ongoing research into novel molecular targets for improving therapy outcomes, as detailed by the study organization.
- Multiple reviews emphasize that glioblastoma’s resistance to standard treatments is driven by complex molecular mechanisms, including robust DNA repair and survival pathways, which supports the rationale for exploring new targets like SET and related proteins 1 3 4 5.
- Previous research highlights the challenge of resistance to both chemotherapy (e.g., temozolomide) and radiotherapy in glioblastoma, driven in part by the tumor’s ability to evade cell death and adapt to therapeutic stress, aligning with the new study’s focus on sensitizing tumor cells via PP2A pathway modulation 3 4 5.
- While clinical improvements in survival have been modest over the past decades, incremental advances with targeted therapies and novel approaches, such as those interfering with protein regulators of cell survival like SET, are seen as promising strategies for future treatment 5 7 9.
Study Overview and Key Findings
Glioblastoma remains among the most aggressive and treatment-resistant forms of brain cancer, with standard therapies often yielding limited extension in patient survival. This new study addresses a critical gap by focusing on the molecular mechanisms underlying glioblastoma’s resilience, specifically targeting proteins that regulate the activity of PP2A—an enzyme involved in cellular growth and repair. By identifying SET as a key suppressor of PP2A and demonstrating that its inhibition can sensitize tumor cells to radiation and chemotherapy in preclinical models, the research offers a potential pathway for improving the efficacy of existing treatments. Importantly, while these findings are promising, they are preliminary and have yet to be evaluated in human clinical trials.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute |
| Journal Name | Cancer Letters |
| Authors | John Ryan Jacob, Shahid M. Nimjee, J. Bradley Elder, Arnab Chakravarti, Kamalakannan Palanichamy |
| Population | Glioblastoma cells in laboratory and animal models |
| Methods | Animal Study |
| Outcome | Sensitivity of glioblastoma cells to radiation and chemotherapy |
| Results | Blocking SET made glioblastoma cells more sensitive to radiation |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus paper database, which includes over 200 million research papers. The following search queries were used to identify relevant literature:
- SET inhibition glioblastoma radiation sensitivity
- glioblastoma treatment resistance mechanisms
- radiation therapy glioblastoma survival outcomes
| Topic | Key Findings |
|---|---|
| What drives treatment resistance in glioblastoma? | - Glioblastoma’s resistance stems from genetic heterogeneity, robust DNA repair, tumor microenvironment influences, and protective barriers, making new molecular targets essential for durable responses 1 3 4 5. - Conventional therapies are limited by the tumor’s ability to evade cell death, regenerate, and adapt to stress, emphasizing the need for approaches that disrupt these adaptive mechanisms 2 3 4 5. |
| What are the current and emerging strategies to improve glioblastoma outcomes? | - Standard care includes surgery, radiation, and temozolomide, but survival improvements have been modest; new approaches such as immunotherapy, tumor-treating fields, and targeted therapies are under investigation 5 6 7 9 10. - Targeting molecular pathways implicated in resistance, including those related to DNA repair and signaling (like PP2A modulation), is seen as promising, though clinical evidence for most approaches remains limited 1 4 5 9. |
| How do molecular features and tumor environment affect therapy response? | - Factors like the blood-brain barrier, tumor heterogeneity, and molecular characteristics (e.g., MGMT methylation, IDH mutation) significantly affect treatment efficacy and patient survival 4 5 8 9. - The microenvironment, including immune suppression and signaling redundancy, contributes to persistent resistance, indicating that combinatorial or pathway-specific interventions may be required 2 4 9. |
What drives treatment resistance in glioblastoma?
Related studies consistently highlight that glioblastoma’s formidable resistance to therapy arises from its complex biology, including genetic heterogeneity, enhanced DNA repair, and the challenging tumor microenvironment. The new study’s focus on targeting the PP2A-regulatory proteins such as SET aligns with these findings, aiming to disrupt survival pathways that enable resistance. While most previous work has underscored the need for new molecular targets, few studies have tested the specific approach of PP2A reactivation to sensitize tumors to standard therapies.
- Glioblastoma’s resistance is multifactorial, involving robust DNA repair, tumor cell plasticity, and an immunosuppressive microenvironment 1 3 4 5.
- The blood–brain barrier and tumor heterogeneity limit the effectiveness of conventional treatments 4 5.
- Novel strategies that interfere with tumor survival signaling—such as through PP2A or its regulators—are increasingly pursued as potential solutions 1 4 5.
- The new study’s approach to weaken resistance by targeting SET and related proteins is supported by the broader literature’s emphasis on the importance of novel molecular interventions 1 3 4 5.
What are the current and emerging strategies to improve glioblastoma outcomes?
The literature shows that while the introduction of concurrent chemoradiotherapy has modestly improved survival, the prognosis for glioblastoma remains poor, underscoring the urgency for innovative treatments. Emerging therapies—including immunotherapies, tumor-treating fields, and molecularly targeted agents—are being explored, but with mixed results in clinical trials. The new study contributes to this evolving landscape by providing a preclinical rationale for targeting SET to potentiate the effects of existing therapies.
- Standard treatments (surgery, radiation, and temozolomide) have only incrementally improved median survival 5 6 7 10.
- Tumor-treating fields and targeted therapies offer additional but still limited survival benefits 7 9.
- Most experimental approaches remain in early or preclinical stages, with few demonstrating significant benefits in large patient cohorts 5 9.
- The current study’s focus on sensitizing tumors to existing modalities by interfering with SET/PP2A is consistent with ongoing efforts to overcome biological resistance 1 4 5.
How do molecular features and tumor environment affect therapy response?
Multiple studies illustrate that molecular characteristics—such as MGMT promoter methylation and IDH status—as well as the tumor microenvironment, play crucial roles in determining response to therapy and overall prognosis. The complexity of these influences further complicates efforts to find universally effective treatments. The new study’s emphasis on modulating cellular signaling pathways adds another potential angle for improving response rates.
- Tumor heterogeneity and molecular markers like MGMT methylation are associated with better or worse outcomes 4 5 8 9.
- The blood-brain barrier and immune microenvironment restrict drug delivery and immune-mediated tumor clearance 2 4 5 9.
- Strategies that address both intrinsic (cellular) and extrinsic (microenvironmental) resistance mechanisms are likely needed for meaningful therapeutic advances 2 4 9.
- The approach of targeting signaling pathways (e.g., SET/PP2A) integrates with the broader need to develop molecularly informed, personalized interventions 1 4 5 9.
Future Research Questions
Further research is essential to validate these preclinical findings in humans, determine the safety and efficacy of SET inhibition, and clarify how such strategies might be integrated into clinical practice. Open questions also remain about the best ways to target PP2A regulators, potential off-target effects, and how to combine these approaches with other emerging therapies for maximal patient benefit.
| Research Question | Relevance |
|---|---|
| Does inhibiting SET in glioblastoma patients improve clinical responses to radiation and chemotherapy? | Direct clinical testing is required to determine if the preclinical benefits of SET inhibition translate into improved outcomes for patients, as most evidence to date is limited to laboratory or animal models 1 5. |
| What are the safety and side effect profiles of targeting SET or PP2A regulators in humans? | Before clinical application, it is crucial to assess potential off-target effects and toxicity, as PP2A is involved in multiple cellular processes and its disruption could have unintended consequences 4 5. |
| Can SET or PP2A modulation be effectively combined with other emerging therapies such as immunotherapy? | Combining different therapeutic modalities may overcome multiple resistance mechanisms; understanding potential synergy or antagonism with immunotherapies and other targeted treatments is essential for integrated therapeutic strategies 2 5 9. |
| Are there biomarkers that predict which glioblastoma patients will respond to SET or PP2A targeted therapies? | Identifying predictive biomarkers could help personalize therapy and target those patients most likely to benefit, given the heterogeneity of glioblastoma and variable responses seen with other targeted approaches 4 8 9. |
| How does SET inhibition impact glioblastoma stem cell survival and tumor recurrence? | Glioblastoma stem cells are thought to drive resistance and recurrence; understanding whether SET inhibition affects these populations will be key for achieving durable responses 3 4 5. |